<HTML>
<HEAD>
<TITLE>REGMA BIO TECHNOLOGIES INC. FORM 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">

<B>
<P>==================================================================================</P>

<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</P>
</B>
<P ALIGN="CENTER">___________________________________________</P>

<B><P ALIGN="CENTER">CURRENT REPORT<br>
</B>Pursuant to Section 13 or 15(d) of the<br>
Securities Exchange Act of 1934</P>

<P ALIGN="CENTER">Date of Report<br>
<B>June 28, 2002</P>


<P ALIGN="CENTER">REGMA BIO TECHNOLOGIES INC.<br>
formerly, LCM EQUITY, INC.<br>
</B>(Exact name of registrant as specified in its charter)</P>

<B><P ALIGN="CENTER">NEVADA<br>
</B>(State or other jurisdiction of incorporation)</P>

<p align=center><center><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=680>
<TR><TD WIDTH="49%" VALIGN="TOP" HEIGHT=26>
<B><P>000-30995</B></TD>
<TD WIDTH="51%" VALIGN="TOP" HEIGHT=26>
<B><P>N/A </B></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP" HEIGHT=28>
<P>(Commission File No.)</TD>
<TD WIDTH="51%" VALIGN="TOP" HEIGHT=28>
<P>(IRS Employer ID)</TD>
</TR>
</CENTER>
</TABLE>


<B><P ALIGN="CENTER">217 Plaza<br>
535 Kings Road<br>
London, England SW10 0SZ<br>
</B>(Address of principal executive offices and Zip Code)</P>

<B>
<P ALIGN="CENTER">44 20 7351 0005<br>
</B>(Registrant's telephone number, including area code)</P>

<P>==================================================================================</P>
<page>
<hr>


<B><P>ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.</P>
</B>
<P>On June 17, 2002, Regma Bio Technologies Limited ("the Company") signed a research agreement with the Institut Pasteur de Lille, in Lille, France. Under this agreement, the Company will sponsor research at the Institut Pasteur de Lille in the development of phage therapies in response to the growing problem of antibiotic resistance, specifically in the area of Mycobacterium tuberculosis (Mtb).</P>

<P>On June 19, 2002, the Company appointed Dr. Juan Pablo Bifani to head the research collaboration with the Institut Pasteur de Lille.</P>

<B><P>ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS</P>
</B>

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=680>
<TR><TD WIDTH="26%" VALIGN="TOP">
<B><P>Exhibit No.</B></TD>
<TD WIDTH="74%" VALIGN="TOP">
<B><P>Description</B></TD>
</TR>
<TR><TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="26%" VALIGN="TOP">
<P>10.1 </TD>
<TD WIDTH="74%" VALIGN="TOP">
<P>Research Agreement</TD>
</TR>
</TABLE>


<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p align=center> - 2 - </p>
<page>
<hr>



<B>
<P ALIGN="CENTER">SIGNATURE</P>
</B>
<P>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P>Dated this 28<SUP>th</SUP>  day of June, 2002.</P>

<TABLE BORDER=0 CELLSPACING=0 WIDTH=680>
<TR><TD WIDTH="39%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="61%" VALIGN="TOP" COLSPAN=2>
<B><P>REGMA BIO TECHNOLOGIES INC.</B></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="53%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP">

<P>&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">
<P>BY:</TD>
<TD WIDTH="53%" VALIGN="TOP">

<P>/s/ David Rooke<br>
Dr. David Rooke, President and Chief Executive Officer</TD>
</TR>
</TABLE>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<page>
<hr>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "regma8k4.htm", "description": "CURRENT REPORT FOR REGMA BIO TECHNOLOGIES INC.", "secsgml_size_bytes": 3844}]
{"company-data": {"conformed-name": "REGMA BIO TECHNOLOGIES LTD", "cik": "0001084226", "assigned-sic": "7389", "irs-number": "980232244", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-30995", "film-number": "02693796"}, "business-address": {"street1": "UNIT 217, PLAZA", "street2": "KINGS ROAD", "city": "LONDON, ENGLAND", "state": "A8", "zip": "SW10OSZ", "phone": "011 44 207 351 0005"}, "mail-address": {"street1": "SAME AS ABOVE"}, "former-company": {"former-conformed-name": "LCM EQUITY INC", "date-changed": "20000711"}}
REGMA BIO TECHNOLOGIES INC. FORM 8-K
==================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report
June 28, 2002
REGMA BIO TECHNOLOGIES INC.
formerly, LCM EQUITY, INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation)
000-30995
N/A
(Commission File No.)
(IRS Employer ID)
217 Plaza
535 Kings Road
London, England SW10 0SZ
(Address of principal executive offices and Zip Code)
44 20 7351 0005
(Registrant's telephone number, including area code)
==================================================================================
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On June 17, 2002, Regma Bio Technologies Limited ("the Company") signed a research agreement with the Institut Pasteur de Lille, in Lille, France. Under this agreement, the Company will sponsor research at the Institut Pasteur de Lille in the development of phage therapies in response to the growing problem of antibiotic resistance, specifically in the area of Mycobacterium tuberculosis (Mtb).
On June 19, 2002, the Company appointed Dr. Juan Pablo Bifani to head the research collaboration with the Institut Pasteur de Lille.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No.
Description
10.1
Research Agreement
- 2 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated this 28
th
day of June, 2002.
REGMA BIO TECHNOLOGIES INC.
BY:
/s/ David Rooke
Dr. David Rooke, President and Chief Executive Officer